[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUP0402270A2 - [1,2,4]Triazolo[1,5-c]pirimidin-5-il-aminok mint adenozin A2a receptor antagonisták és az ezeket tartalmazó gyógyszerkészítmények - Google Patents

[1,2,4]Triazolo[1,5-c]pirimidin-5-il-aminok mint adenozin A2a receptor antagonisták és az ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0402270A2
HUP0402270A2 HU0402270A HUP0402270A HUP0402270A2 HU P0402270 A2 HUP0402270 A2 HU P0402270A2 HU 0402270 A HU0402270 A HU 0402270A HU P0402270 A HUP0402270 A HU P0402270A HU P0402270 A2 HUP0402270 A2 HU P0402270A2
Authority
HU
Hungary
Prior art keywords
triazolo
pyrimidin
adenosine
amines
pharmaceutical compositions
Prior art date
Application number
HU0402270A
Other languages
English (en)
Inventor
Julius J. Matasi
John P. Caldwell
Deen Tulshian
Lisa S. Silverman
Bernard R. Neustadt
Original Assignee
Schering Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp. filed Critical Schering Corp.
Publication of HUP0402270A2 publication Critical patent/HUP0402270A2/hu
Publication of HUP0402270A3 publication Critical patent/HUP0402270A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A jelen találmány (I) általános képletű vegyületekre vagy ezekgyógyászatilag elfogadható sóira vagy szolvátjaira vonatkozik, melyképletben R, R2 és R3 jelentése a leírásban megadott. A találmánytovábbá ezeket a vegyületeket tartalmazó és stroke vagy központiidegrendszeri betegségek kezelésére szolgáló gyógyszerkészítményekreis vonatkozik. Ó
HU0402270A 2001-11-30 2002-11-26 [1,2,4]triazolo[1,5-c]pyrimidin-5-yl-amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing them HUP0402270A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33429301P 2001-11-30 2001-11-30
PCT/US2002/038134 WO2003048164A2 (en) 2001-11-30 2002-11-26 Adenosine a2a receptor antagonists

Publications (2)

Publication Number Publication Date
HUP0402270A2 true HUP0402270A2 (hu) 2005-02-28
HUP0402270A3 HUP0402270A3 (en) 2008-09-29

Family

ID=23306533

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402270A HUP0402270A3 (en) 2001-11-30 2002-11-26 [1,2,4]triazolo[1,5-c]pyrimidin-5-yl-amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing them

Country Status (19)

Country Link
US (1) US7041666B2 (hu)
EP (1) EP1453835B1 (hu)
JP (2) JP4284181B2 (hu)
KR (1) KR20050044607A (hu)
CN (1) CN1596258A (hu)
AR (1) AR038366A1 (hu)
AT (1) ATE317844T1 (hu)
AU (1) AU2002346572A1 (hu)
CA (1) CA2468681C (hu)
DE (1) DE60209251T2 (hu)
ES (1) ES2258164T3 (hu)
HK (1) HK1064100A1 (hu)
HU (1) HUP0402270A3 (hu)
IL (1) IL161572A0 (hu)
MX (1) MXPA04005156A (hu)
PE (1) PE20030739A1 (hu)
TW (1) TW200300686A (hu)
WO (1) WO2003048164A2 (hu)
ZA (1) ZA200404160B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1544200A1 (en) * 2002-09-24 2005-06-22 Kyowa Hakko Kogyo Co., Ltd. 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE
NZ540493A (en) 2002-12-19 2008-04-30 Schering Corp Uses of adenosine A2a receptor antagonists
US20060106040A1 (en) 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
WO2004092172A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
JP4800216B2 (ja) * 2003-10-24 2011-10-26 エグゼリクシス， インコーポレイテッド ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法
AR050926A1 (es) * 2004-09-03 2006-12-06 Astrazeneca Ab Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac)
JPWO2006129626A1 (ja) * 2005-05-30 2009-01-08 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
KR20100022080A (ko) * 2007-05-24 2010-02-26 미쓰비시 타나베 파마 코퍼레이션 뇌경색 치료제
JP2010531364A (ja) * 2007-06-25 2010-09-24 ニューロジェン・コーポレーション ピペラジニルオキソアルキルテトラヒドロ−β−カルボリンおよび関連類似体
US20100093764A1 (en) * 2008-10-13 2010-04-15 Devraj Chakravarty AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093756A1 (en) * 2008-10-13 2010-04-15 Berbay J Kent HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
RU2472257C1 (ru) 2008-11-25 2013-01-10 Ниссан Мотор Ко., Лтд. Электропроводный узел и топливный элемент с полимерным электролитом с его использованием
EP2424840B1 (en) * 2009-04-27 2014-08-06 Boehringer Ingelheim International GmbH Cxcr3 receptor antagonists
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
CA2812378C (en) * 2010-09-24 2016-11-29 Advinus Therapeutics Limited Fused tricyclic compounds as adenosine receptor antagonist
WO2012127472A1 (en) * 2011-03-22 2012-09-27 Mapi Pharma Ltd. Process and intermediates for the preparation of preladenant and related compounds
PL3611174T3 (pl) * 2017-04-07 2022-08-08 Medshine Discovery Inc. Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a
JP7474709B2 (ja) * 2018-02-27 2024-04-25 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
JP7406691B2 (ja) * 2018-04-28 2023-12-28 イノレイク・バイオファーマ（ハンジョウ）・カンパニー・リミテッド トリアゾロピリミジン系化合物の結晶形、塩のタイプおよびその調製方法
MA52940A (fr) * 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
TWI820209B (zh) * 2018-09-12 2023-11-01 大陸商迪哲（江蘇）醫藥股份有限公司 三唑并－嘧啶化合物及其用途
MA55142A (fr) 2018-11-20 2022-02-23 Merck Sharp & Dohme Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019385905B2 (en) 2018-11-30 2023-01-12 Merck Sharp & Dohme Llc 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
AU2019401649A1 (en) 2018-12-20 2021-07-08 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
WO2020128036A1 (en) * 2018-12-21 2020-06-25 Ryvu Therapeutics S.A. Modulators of the adenosine a2a receptor
TWI829857B (zh) * 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ES2165393T3 (es) 1993-07-27 2002-03-16 Kyowa Hakko Kogyo Kk Remedio contra la enfermedad de parkinson.
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
CA2284737C (en) 1997-03-24 2007-03-13 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]triazolo[1,5-c]pyrimidine derivatives
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
IL142128A0 (en) 1998-09-22 2002-03-10 Kyowa Hakko Kogyo Kk [1,2,4] triazolo [1,5-c] pyrimidine derivatives
US6630475B2 (en) 2000-05-26 2003-10-07 Schering Corporation Adenosine A2a receptor antagonists
WO2002079204A1 (fr) * 2001-03-28 2002-10-10 Kyowa Hakko Kogyo Co., Ltd. Derive 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine
DE60219196T2 (de) 2001-11-30 2008-01-03 Schering Corp. BICYCLISCHE [1,2,4]-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN

Also Published As

Publication number Publication date
WO2003048164A2 (en) 2003-06-12
AR038366A1 (es) 2005-01-12
PE20030739A1 (es) 2003-08-28
CN1596258A (zh) 2005-03-16
JP4284181B2 (ja) 2009-06-24
WO2003048164A3 (en) 2003-10-16
ES2258164T3 (es) 2006-08-16
IL161572A0 (en) 2004-09-27
HUP0402270A3 (en) 2008-09-29
JP2005511698A (ja) 2005-04-28
EP1453835A2 (en) 2004-09-08
JP2008303217A (ja) 2008-12-18
HK1064100A1 (en) 2005-01-21
CA2468681A1 (en) 2003-06-12
US7041666B2 (en) 2006-05-09
DE60209251T2 (de) 2006-11-09
MXPA04005156A (es) 2004-08-11
KR20050044607A (ko) 2005-05-12
ZA200404160B (en) 2005-04-08
EP1453835B1 (en) 2006-02-15
CA2468681C (en) 2011-01-25
US20030212080A1 (en) 2003-11-13
TW200300686A (en) 2003-06-16
AU2002346572A1 (en) 2003-06-17
DE60209251D1 (de) 2006-04-20
ATE317844T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
HUP0402270A2 (hu) [1,2,4]Triazolo[1,5-c]pirimidin-5-il-aminok mint adenozin A2a receptor antagonisták és az ezeket tartalmazó gyógyszerkészítmények
ATE353013T1 (de) Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
SE9701398D0 (sv) Novel compounds
SI1427708T1 (sl) Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MY132106A (en) New pyridazin-3(2h)-one derivatives
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
NZ522326A (en) Adenosine A2A receptor antagonists
CA2468649A1 (en) Adenosine a2a receptor antagonists
HK1098742A1 (en) Substituted 1h-pyrrolo [3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase i epsilon
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
IL174678A0 (en) Arylindenophyridines and arylindenophyrimidines and their use as adenosine a2a receptor antagonist
IL159880A0 (en) Arylsulfonyl derivatives with 5-ht6 receptor affinity
ATE233754T1 (de) Diphenyl-piperidin derivate
HK1090543A1 (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
TW200505916A (en) 7-azaindoles and the use thereof as therapeutic agents
HUP0303329A2 (hu) Új fenil-piperazinok
SE0100296D0 (sv) New compounds
SE0100297D0 (sv) New compounds
SE0100295D0 (sv) New compounds
DE50212538D1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzoäcüfluoren-6-carbonsäurederivate als nmda-antagonisten
MY135855A (en) "pyrrolopyrimidinone derivatives, process of preparation and use"

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished